Patents Assigned to HALIA THERAPEUTICS, INC.
  • Inhibitors of LRRK2 kinase
    Patent number: 11866423
    Abstract: Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R1a, R1b, R2, and L are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of LRRK2 kinase are also provided.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: January 9, 2024
    Assignee: HALIA THERAPEUTICS, INC.
    Inventors: David James Bearss, John Sai Keong Kauwe, III, Alexis Henri Abel Mollard
  • Inhibitors of NEK7 kinase
    Patent number: 11713321
    Abstract: Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein, A, X, Y, R1, R2, R3, R4 and R5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of the NLRP3 inflammasome are also provided.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: August 1, 2023
    Assignee: HALIA THERAPEUTICS, INC.
    Inventors: David James Bearss, John Sai Keong Kauwe, III, Alexis Henri Abel Mollard
  • Inhibitors of LRRK2 kinase
    Patent number: 11578061
    Abstract: Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R1a, R1b, R2, and L are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of LRRK2 kinase are also provided.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: February 14, 2023
    Assignee: HALIA THERAPEUTICS, INC.
    Inventors: David James Bearss, John Sai Keong Kauwe, III, Alexis Henri Abel Mollard
  • Inhibitors of NEK7 kinase
    Patent number: 11161852
    Abstract: Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein, A, X, Y, R1, R2, R3, R4 and R5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of the NLRP3 inflammasome are also provided.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: November 2, 2021
    Assignee: HALIA THERAPEUTICS, INC.
    Inventors: David James Bearss, John Sai Keong Kauwe, III, Alexis Henri Abel Mollard